GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beryl Drugs Ltd (BOM:524606) » Definitions » Cyclically Adjusted Revenue per Share

Beryl Drugs (BOM:524606) Cyclically Adjusted Revenue per Share : ₹39.38 (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Beryl Drugs Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Beryl Drugs's adjusted revenue per share for the three months ended in Mar. 2024 was ₹5.938. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹39.38 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Beryl Drugs's average Cyclically Adjusted Revenue Growth Rate was 5.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Beryl Drugs was 5.50% per year. The lowest was 5.50% per year. And the median was 5.50% per year.

As of today (2024-06-12), Beryl Drugs's current stock price is ₹36.64. Beryl Drugs's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹39.38. Beryl Drugs's Cyclically Adjusted PS Ratio of today is 0.93.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beryl Drugs was 1.10. The lowest was 0.16. And the median was 0.34.


Beryl Drugs Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Beryl Drugs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beryl Drugs Cyclically Adjusted Revenue per Share Chart

Beryl Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 33.57 35.01 37.30 39.38

Beryl Drugs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.30 38.28 38.86 39.52 39.38

Competitive Comparison of Beryl Drugs's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beryl Drugs's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Beryl Drugs's Cyclically Adjusted PS Ratio falls into.



Beryl Drugs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Beryl Drugs's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.938/153.0345*153.0345
=5.938

Current CPI (Mar. 2024) = 153.0345.

Beryl Drugs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 7.235 94.103 11.766
201409 6.462 96.780 10.218
201412 5.629 96.780 8.901
201503 6.805 97.163 10.718
201506 8.995 99.841 13.787
201509 7.919 101.753 11.910
201512 5.580 102.901 8.299
201603 3.174 102.518 4.738
201606 5.994 105.961 8.657
201609 5.900 105.961 8.521
201612 5.078 105.196 7.387
201703 4.688 105.196 6.820
201706 9.573 107.109 13.678
201709 6.347 109.021 8.909
201712 7.163 109.404 10.020
201803 8.391 109.786 11.696
201806 8.163 111.317 11.222
201809 6.974 115.142 9.269
201812 5.957 115.142 7.917
201903 3.810 118.202 4.933
201906 8.397 120.880 10.631
201909 6.413 123.175 7.968
201912 4.387 126.235 5.318
202003 5.590 124.705 6.860
202006 5.365 127.000 6.465
202009 6.421 130.118 7.552
202012 4.118 130.889 4.815
202103 11.658 131.771 13.539
202106 9.098 134.084 10.384
202109 6.574 135.847 7.406
202112 6.243 138.161 6.915
202203 6.771 138.822 7.464
202206 9.715 142.347 10.444
202209 15.077 144.661 15.950
202212 15.989 145.763 16.787
202303 12.218 146.865 12.731
202306 16.050 150.280 16.344
202309 15.800 151.492 15.961
202312 14.940 152.924 14.951
202403 5.938 153.035 5.938

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Beryl Drugs  (BOM:524606) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Beryl Drugs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=36.64/39.38
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beryl Drugs was 1.10. The lowest was 0.16. And the median was 0.34.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Beryl Drugs Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Beryl Drugs's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Beryl Drugs (BOM:524606) Business Description

Industry
Traded in Other Exchanges
N/A
Address
133, Kanchan Bagh, Ground Floor, Indore, MP, IND, 452001
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.

Beryl Drugs (BOM:524606) Headlines

No Headlines